Ask AI
Adult Pneumococcal Disease Prevention

CE / CME

Elucidating the Rapid Changes in Pneumococcal Disease Prevention in Adults

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: June 09, 2026

Expiration: June 08, 2027

Activity

Progress
1 2
Course Completed

References

  1. Centers for Disease Control and Prevention. Pneumococcal disease symptoms and complications. cdc.gov/pneumococcal/signs-symptoms/index.html. Accessed May 28, 2026.
  2. Narciso AR, Dookie R, Nannapaneni P, et al. Streptococcus pneumoniae epidemiology, pathogenesis and control. Nat Rev Microbiol. 2025;23:256-271. 
  3. Womack J, Kropa J. Community-acquired pneumonia in adults: rapid evidence review. Am Fam Physician. 2022;105:625-630.
  4. Mangen MJ, Huijts SM, Bonten MJ, et al. The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. BMC Infect Dis. 2017;17:208. 
  5. Centers for Disease Control and Prevention. ABCs bact facts interactive data dashboard. cdc.gov/abcs/bact-facts/data-dashboard.html. Accessed May 28, 2026.
  6. Chen H, Matsumoto H, Horita N, et al. Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis. Sci Rep. 2021;11:11865. 
  7. Darkwah S, Somda NS, Mahazu S, et al. Pneumococcal serotypes and their association with death risk in invasive pneumococcal disease: a systematic review and meta-analysis. Front Med (Lausanne). 2025;12:1566502. 
  8. Bennett JC, Deloria Knoll M, Kagucia EW, et al. Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis. 2025;25:457-470.
  9. King LM, Andrejko KL, Kobayashi M, et al. Pneumococcal serotype distribution and coverage of existing and pipeline pneumococcal vaccines. J Infect Dis. 2025;232:e609-e620.
  10. Weycker D, Farkouh RA, Strutton DR, et al. Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Serv Res. 2016 May 13;16:182. 
  11. Centers for Disease Control and Prevention. Pneumococcal disease: causes and how it spreads. cdc.gov/pneumococcal/causes/index.html. Accessed May 28, 2026.
  12. Pneumococcal vaccine polyvalent [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; 2021.
  13. Centers for Disease Control and Prevention. Pneumococcal vaccine safety. cdc.gov/vaccine-safety/vaccines/pneumococcal.html. Accessed May 28, 2026.
  14. Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-valent pneumococcal conjugate vaccine among U.S. adults: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:793-798.
  15. Centers for Disease Control and Prevention. Summary of work group interpretation of EtR and policy options: PCV use in adults aged ≥50 years. cdc.gov/acip/downloads/slides-2024-10-23-24/04-Kobayashi-Pneumococcal-508.pdf. Accessed May 28, 2026.
  16. Kobayashi M, Leidner AJ, Gierke R, et al. Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74:1-8.
  17. Centers for Disease Control and Prevention. Pneumococcal vaccine timing for adults. cdc.gov/pneumococcal/downloads/Vaccine-Timing-Adults-JobAid.pdf. Accessed May 28, 2026.